Browse the evidence

Semaglutide induces body weight loss and metabolic remodeling beyond caloric restriction alone, driven by intake-independent mechanisms including adipose tissue browning, increased sympathetic innervation, and sustained locomotor activity.

Semaglutide provides metabolic benefits that go beyond simply eating less. It promotes fat loss through biological changes like increasing brown fat activity and reducing fat cell size, independent of how much you eat. This suggests that patients may achieve better results with semaglutide than with dieting alone, even if their food intake is similar.

The 'borderline stage' of obesity (BMI 28-31.9 kg/m²) is a critical transitional phase characterized by elevated triglycerides, insulin resistance, and low-grade chronic inflammation, representing a vital window for early intervention to prevent clinical obesity.

If your BMI is between 28 and 31.9, do not assume you are safe. Look for metabolic red flags: high triglycerides, insulin resistance, or low-grade inflammation. This is your window to intervene with lifestyle changes (diet, activity) before clinical obesity and its complications set in.

Discontinuation of semaglutide or tirzepatide after 3-12 months of treatment results in negligible average weight change (mean +0.5% for obesity indication, -1.3% for T2D) over the subsequent year, driven by high rates of medication reinitiation (19.6%) or switching to alternative treatments (35.2%).

If you stop semaglutide or tirzepatide, do not assume you will regain all your weight. In clinical practice, most patients either restart the medication or switch to another treatment, which keeps average weight change very small (near zero) over the next year. However, individual results vary widely, so you must actively engage with your healthcare provider to select a replacement strategy (medication or lifestyle) immediately upon discontinuation to avoid regain.

Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.

If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.

Shifting the Australian population's BMI to an optimal level of ≤25 kg/m² yields substantial health gains, specifically 2.00 million undiscounted Health Adjusted Life Years (HALYs) over 20 years and 20.4 million over the remaining lifetime.

For public health policy, this simulation confirms that population-wide strategies to maintain a BMI under 25 kg/m² are among the most effective interventions for extending healthy life. The benefits are not just individual but systemic, significantly reducing the burden of chronic diseases like heart disease, diabetes, and osteoarthritis, with the greatest relative health improvements occurring in socioeconomically disadvantaged communities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce body weight, BMI, and waist circumference in patients with psychiatric disorders and obesity, with efficacy comparable to or slightly lower than that observed in non-psychiatric populations.

If you have a psychiatric condition and are overweight, GLP-1 medications (like semaglutide or liraglutide) are a proven, effective option for losing weight, even if you take other psychiatric meds. You will likely lose about 5 kg (11 lbs) on average, which is less than in people without mental health conditions, but still significant. Side effects like nausea are common but usually mild and don't cause most people to stop treatment. Discuss this with your doctor as a priority for metabolic health.

A clinical risk model predicting new-onset diabetes (using HbA1c, fasting glucose, age, BMI, and TG/HDL ratio) identifies patients who derive significantly greater absolute risk reduction from pharmacological weight loss therapy (lorcaserin) compared to low-risk patients, despite similar hazard ratios.

If you have cardiovascular risk factors and are considering weight loss medication, ask your doctor about your specific risk of developing diabetes. A simple calculation using your age, BMI, and blood markers can show if you are likely to get significant absolute protection from diabetes by using weight-loss drugs. High-risk patients gain much more absolute benefit than low-risk patients, even if the relative effectiveness looks similar.

High-risk patients on blood pressure, lipid, or glucose-lowering medications in primary care settings frequently fail to achieve guideline-recommended lifestyle and medical risk factor targets, indicating a significant gap between evidence-based guidelines and clinical practice.

If you are at high risk for heart disease, taking medication is not enough. You must also address lifestyle factors like smoking, weight, and physical activity. The study shows that most people on medication still fail to reach health targets. Focus on quitting smoking, maintaining a healthy weight, and staying active alongside your medical treatment.

Pharmacotherapy for obesity is indicated for patients with BMI >= 30 kg/m2 or >= 27 kg/m2 with comorbidities, and efficacy is defined as >= 5% weight loss after 3 months.

If your BMI is 30+ (or 27+ with health issues), ask about medication. It's not a failure; it's a tool. If you don't lose at least 5% in 3 months, the drug isn't working for you.

Bariatric surgery is indicated for patients with BMI >= 40 kg/m2 or >= 35 kg/m2 with comorbidities, and offers benefits beyond weight loss including glycemic control and improved life expectancy.

If your BMI is 40+ (or 35+ with health issues), surgery is a valid option. It's not just weight loss; it can fix diabetes and other issues. Choose an experienced surgeon and commit to long-term follow-up.

Most plant-based meat analogues on the market have insufficient protein quality or quantity compared to animal meat, and very few are fortified with essential micronutrients like Vitamin B12 or Iron.

Do not assume plant-based meats are nutritionally complete. Check labels for Vitamin B12 and Iron fortification, as only 12% of products include them. Also, verify protein quality; many analogues have lower digestible indispensable amino acid scores (DIAAS) than meat. If you eat these frequently, consider a B12 supplement and ensure you are getting enough total protein.

Higher relative intake of dietary fat is inversely associated with heart failure risk, with Mendelian randomization confirming a causal protective effect.

If you are concerned about heart failure, this study suggests that restricting fat intake may not be the best strategy. Higher relative fat intake was linked to a lower risk of heart failure. You do not need to fear fat; instead, focus on a balanced diet. Consult your doctor for personalized advice, especially if you have existing heart conditions.

Higher relative intake of dietary protein is inversely associated with the risk of stroke, with Mendelian randomization confirming a causal protective effect.

If you are concerned about stroke, this study suggests that ensuring adequate protein intake may be beneficial. Higher relative protein intake was linked to a lower risk of stroke. Include protein-rich foods in your diet. Consult your doctor for personalized advice, especially if you have existing kidney conditions.

Higher intake of total fat, saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids is associated with lower prevalence of covert brain infarcts and white matter hyperintensities, and higher cognitive scores (DSST).

Don't fear fat. This study found that people who ate more fat, including saturated, monounsaturated, and polyunsaturated fats, had less brain injury on MRI and better cognitive scores. Try incorporating more healthy fats into your diet, such as those found in nuts, seeds, and olive oil.

Bariatric surgery (specifically Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) alters gut peptide profiles by increasing postprandial PYY and decreasing postprandial total and acylated ghrelin, which correlates with reduced hunger and increased fullness, whereas low-calorie diet does not produce these favorable gut peptide changes.

Bariatric surgery changes your gut hormones to help you feel fuller faster and less hungry, which supports weight loss. This hormonal change is not seen with dieting alone. You may need to adjust your eating habits to accommodate these changes, such as eating smaller meals and chewing thoroughly.

Among patients with severe obesity treated with semaglutide 2.4 mg/week, those with higher intuitive eating scores and lower anxiety/depression levels (Intuitive Eaters Group) achieve significantly greater weight loss than those with higher emotional distress and lower intuitive eating scores (Emotionally Driven Eaters Group).

If you are taking semaglutide for severe obesity, your mental health and eating mindset matter for your results. Patients with high emotional distress and lower intuitive eating skills tend to lose less weight than those with better emotional regulation and intuitive eating habits. To maximize your weight loss, consider integrating psychological support or intuitive eating strategies alongside your medication, as these factors significantly influence your trajectory.

In oncology patients, muscle-specific strength (MSS) estimated via anthropometry (body weight or calf circumference) or bioimpedance (BIA) provides a reliable alternative to DXA-derived MSS, enabling functional assessment in resource-limited settings.

For cancer patients or clinicians without access to DXA scanners, you can accurately estimate muscle quality by dividing handgrip strength by body weight or calf circumference. This method correlates very strongly with the gold standard DXA test, allowing for effective monitoring of sarcopenia and treatment response in routine clinical settings.

Administering semaglutide to US adults with type 2 diabetes who meet SUSTAIN-6 trial eligibility criteria prevents approximately 75,681 primary composite cardiovascular events annually.

If you have Type 2 Diabetes and meet specific risk criteria (age over 50 with heart/kidney issues, or over 60 with additional risk factors), asking your doctor about semaglutide could potentially prevent tens of thousands of major heart events in your demographic group annually. The medication is a weekly injection that has been shown to significantly lower the risk of heart attack, stroke, and cardiovascular death in clinical trials.

Treatment with the Epitomee shape-shifting hydrogel capsule combined with lifestyle intervention significantly improves health-related quality of life (HRQOL), specifically in Physical Function and total scores, compared to placebo in adults with overweight or obesity.

If you are overweight or have obesity (BMI 27-40) and struggle with portion control, this hydrogel capsule may help improve your quality of life and physical function more than lifestyle changes alone. You take one capsule with a large glass of water 30 minutes before your two main meals daily. It expands in your stomach to help you feel full sooner. This approach is particularly useful if you want to avoid medications or have contraindications to them. The benefits are most pronounced if you lose 10% or more of your body weight, but even modest loss improves physical function scores significantly.

Dietary capsinoids (9 mg/day) increase resting energy expenditure and brown adipose tissue density in healthy and overweight middle-aged adults.

Take 9 mg of capsinoids daily. This simple supplement has been shown in human trials to increase your resting energy expenditure and increase the amount of active brown fat, even in overweight individuals. It is a low-effort way to slightly boost your metabolic rate.

Caffeine (375 mg capsule or equivalent from coffee/tea) increases energy expenditure and brown adipose tissue activity in physically active humans.

Consume 375 mg of caffeine (or equivalent from coffee/tea) 30 minutes before activity. This has been shown to increase energy expenditure and activate brown fat, particularly in physically active men. It is a practical way to leverage a common substance for metabolic benefit.

Beta-3 adrenergic receptor agonists (e.g., mirabegron) increase brown adipose tissue activation, metabolic rate, and reduce blood glucose, but are limited by adverse cardiovascular effects.

Mirabegron increases brown fat and metabolism but causes high blood pressure and heart rate. It is not recommended for weight loss due to these cardiovascular risks.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce a weight loss plateau over time, suggesting that appetite suppression alone is insufficient for sustained weight management and highlighting the need for complementary thermogenic strategies.

If you are on a GLP-1 medication like semaglutide or liraglutide and your weight loss has stalled after the first year, this is a common physiological plateau, not a failure. The medication's appetite-suppressing effect has maxed out. To continue losing weight, you may need to add strategies that increase energy expenditure, such as exercise-induced thermogenesis or potentially future thermogenic medications, rather than just relying on the drug alone.

GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) are primarily utilized in clinical practice for obesity treatment rather than type 2 diabetes, with obesity being the dominant indication across these agents.

If you are using GLP-1 medications like Ozempic, Wegovy, or Mounjaro, you are part of a large group using them primarily for weight management, not just blood sugar control. If you dislike injections, ask about oral semaglutide. Be aware that newer drugs like Tirzepatide may be expensive and not covered by insurance, which can lead to stopping treatment early.